Prescriber's Corner

Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma

Bradley J. Yelvington, PharmD

Vanderbilt University Medical Center—Pharmacy, Nashville, Tennessee

Author’s disclosures of conflicts of interest are found at the end of this article.

Bradley J. Yelvington, PharmD, 1301 Medical Center Drive, Room 3910, The Vanderbilt Clinic, Nashville, Tennessee 37232. E-mail: bradley.j.yelvington@vanderbilt.edu


J Adv Pract Oncol 2018;9(5):530–534 | https://doi.org/10.6004/jadpro.2018.9.5.7 | © 2018 Harborside™


  

ABSTRACT

Abstract

Rituximab and hyaluronidase human is a new subcutaneous formulation of rituximab that was recently approved by the US Food and Drug Administration for the treatment of adults with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. With data to support noninferior pharmacokinetics, similar outcomes, and comparable adverse events, rituximab and hyaluronidase human may offer a suitable alternative to intravenous rituximab that could improve convenience for patients and better utilize health-care resources.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.